Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03740997 · ClinicalTrials.gov registry record · Phase 4

Study to Determine Safety and Dosage of OPTISON in Pediatric Participants

A Phase 4 study of Transthoracic Echocardiography and Suspected or Known Structural or Functional Cardiac Abnormality, sponsored by GE Healthcare.

Completed
Registry status
Phase 4
Development phase
39
Enrollment target
8
Study locations

NCT03740997 is a Phase 4 study of Transthoracic Echocardiography and Suspected or Known Structural or Functional Cardiac Abnormality that has completed, run by GE Healthcare. The registered enrollment target is 39 participants. The trial reports 8 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03740997, a Phase 4 study of Transthoracic Echocardiography and Suspected or Known Structural or Functional Cardiac Abnormality, has completed, sponsored by GE Healthcare.

COMPLETED
Registry status
Phase 4
Development phase
39 participants
Enrollment target
8
Study locations

Study Summary

Study to determine the safety and appropriate dosage of OPTISON in pediatric participants since OPTISON has been tested in adult participants only during the clinical development

Interventions

  • DRUG Optison

Study Locations (8)

Arizona

  • Phoenix Children's Hospital - Phoenix

California

  • Children's Hospital Los Angeles - Los Angeles

Georgia

  • MCG Health, Inc. - Augusta

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Maryland

  • Johns Hopkins University School of Medicine - Baltimore

New York

  • Cohen Children's Medical Center of New York - Lake Success

Ohio

  • Cleveland Clinic Foundation - Cleveland

Texas

  • Baylor College of Medicine - Houston

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2020-12-01
Est. Completion 2023-03-30
Phase Phase 4

Sponsor

GE Healthcare

99 total trials

What the Registry Record Tells You About NCT03740997

The ClinicalTrials.gov registry entry for NCT03740997 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Transthoracic Echocardiography appearing as the primary indexed condition, and to 1 intervention - of which Optison is the first listed.

NCT03740997 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Arizona, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT03740997 about?

NCT03740997 is a clinical study titled "Study to Determine Safety and Dosage of OPTISON in Pediatric Participants". Study to determine the safety and appropriate dosage of OPTISON in pediatric participants since OPTISON has been tested in adult participants only during the clinical development

What is the current status of trial NCT03740997?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 39 participants. The study started on 2020-12-01. Estimated completion is 2023-03-30.

What conditions does trial NCT03740997 study?

This clinical trial studies the following conditions: Transthoracic Echocardiography, Suspected or Known Structural or Functional Cardiac Abnormality.

What interventions are being tested in trial NCT03740997?

The interventions under investigation include: Optison (DRUG).

Who is sponsoring clinical trial NCT03740997?

This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03740997 being conducted?

This trial has 8 study locations across Arizona, California, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.